Core Viewpoint - The stock of药捷安康-B (02617) has surged over 50% since its listing on June 23, with a current price increase of 21 times from the initial offering price of 13.15 HKD, reaching 287 HKD and a market capitalization exceeding 110 billion HKD [1] Group 1: Stock Performance - The stock price has increased by 49.09% as of the latest report, with a trading volume of 2.199 billion HKD and a total market value surpassing 110 billion HKD [1] - The stock has experienced a significant volatility with an amplitude of 71% and a turnover rate of only 3.14% [1] Group 2: Regulatory and Clinical Developments - The company has been included in the Hong Kong Stock Connect list effective from September 8, as announced by the Shanghai and Shenzhen Stock Exchanges [1] - On September 10, the company announced that its core product, Tiengogatin combined with Fulvestrant, received clinical implied approval from the National Medical Products Administration for a Phase II trial in treating hormone receptor-positive (HR+) and HER2-negative or low-expressing recurrent or metastatic breast cancer, expected to be completed by September 10, 2025 [1] Group 3: Financial Performance - The company reported no revenue from its main business in the first half of the year, with other income declining from 10.4 million HKD in the first half of 2024 to 3.6 million HKD, a decrease of 65.1% [1] - The pre-tax loss for the first half of the year was 123 million HKD, an improvement compared to a loss of 160 million HKD in the same period of 2024 [1] Group 4: Shareholding Structure - The founder, Wu Yongqian, holds a significant stake of 32.98%, contributing to a limited market float due to substantial institutional holdings [1]
药捷安康-B涨超50%破顶 不到三个月股价飙涨21倍 总市值突破1100亿港元